Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes.
Stephen Harrow, David A Palma, Robert Olson...
https://pubmed.ncbi.nlm.nih.gov/35643253/Actively Recruiting
Led by Istituto Clinico Humanitas · Updated on 2026-02-11
300
Participants Needed
28
Research Sites
N/A
Total Duration
Oligometastatic breast cancer occurs when breast cancer has spread to a limited number of other body sites. Patients with this condition may live longer than those with more widespread metastases. Researchers are investigating whether adding local treatments like stereotactic body radiotherapy SBRT, a non-invasive radiation therapy delivering high doses in a few sessions, can improve disease control and survival in these patients. This study is a multicenter retrospective analysis aiming to better understand SBRTs role in this setting. The study focuses on patients who have received SBRT to their oligometastatic sites, delivering a minimum radiation dose of 50 Gy EQD2 in up to 12 sessions, following the Oligocare definition. This local treatment is considered alongside standard systemic therapies like chemotherapy or hormonal therapy. The study collects data from treatments performed between January 2010 and December 2023 to evaluate outcomes. Participants data will be reviewed retrospectively to measure progression-free survival as the primary outcome. Secondary outcomes include local control of treated sites, overall survival, and acute or late radiation-related toxicities. The study covers treatments applied outside the brain and aims to provide insights into the safety and effectiveness of SBRT in managing oligometastatic breast cancer. The overall participation involves analysis of existing patient records from multiple centers up to the end of 2023.
CONDITIONS
stereOtactic Body RadIothErapy for exTracranial oligomeTastAtic Breast Cancer: Multi Institutional Retrospective Database
R
Ruggero Spoto, MD, Radiation oncologist
L
Laura Bonavita, Master Degree
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Istituto Clinico Humanitas
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Varies depending on treatment schedule
Participants receive stereotactic body radiotherapy (SBRT) to oligometastatic sites with a minimum dose of 50Gy EQD2 in up to 12 fractions.
Up to 12 treatment sessions
Duration - From January 2010 to December 2023
Participants are monitored for progression-free survival, local control, overall survival, and treatment-related toxicity.
Visit schedule varies based on clinical follow-up
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Stephen Harrow, David A Palma, Robert Olson...
https://pubmed.ncbi.nlm.nih.gov/35643253/Annemiek van Ommen-Nijhof, Tessa G Steenbruggen, Laura Capel...
https://pubmed.ncbi.nlm.nih.gov/36549169/Mayako Terao, Naoki Niikura
https://pubmed.ncbi.nlm.nih.gov/35117868/Istituto Clinico Humanitas
Lead Sponsor